Cintia Piccina
CIK 1907199 · Chief Commercial Officer · last filed 2025-02-20
Cintia Piccina is a Chief Commercial Officer who has filed 9 SEC Form 4 insider transactions across 2 companies since 2022. The most recent filing, for ADAP, was dated Feb 20, 2025. Across all open-market trades the lifetime net is −$89.8K, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
2
9
-$89.8K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Adaptimmune Therapeutics PLC (ADAP) Delisted | Chief Commercial Officer | 18,421 | $0.06 | $1.1K | -$89.8K | 8 | 2025-02-20 |
| Kalaris Therapeutics, Inc. (ALVR) Delisted | Chief Commercial Officer | 147,000 | $9.81 | $1.44M | $0 | 1 | 2023-07-05 |
Recent Filings
9 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-02-20 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-01-15 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Sell (S) | −12,991 | -$7.5K | EDGAR |
| 2024-06-18 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Sell (S) | −24,531 | -$22.8K | EDGAR |
| 2024-03-18 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-07-05 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Grant (A) | +147,000 | $0 | EDGAR |
| 2023-01-31 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Sell (S) | −11,890 | -$22.2K | EDGAR |
| 2023-01-17 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-08-01 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Sell (S) | −21,040 | -$37.3K | EDGAR |
| 2022-01-31 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Grant (A) | — | $0 | EDGAR |